|
POFUT1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.10855769008822E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.19388959724165E-12 |
| Normal-vs-Stage2 |
1.79070000050352E-07 |
| Normal-vs-Stage3 |
2.10709227843608E-12 |
| Normal-vs-Stage4 |
2.46469511466785E-14 |
| Stage1-vs-Stage2 |
5.873800E-02 |
| Stage1-vs-Stage3 |
3.597200E-01 |
| Stage1-vs-Stage4 |
3.710400E-02 |
| Stage2-vs-Stage3 |
3.079900E-02 |
| Stage2-vs-Stage4 |
5.483600E-03 |
| Stage3-vs-Stage4 |
3.437800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.05435668476639E-12 |
| Normal-vs-AfricanAmerican |
7.69330000000013E-05 |
| Normal-vs-Asian |
2.63650212772859E-11 |
| Caucasian-vs-AfricanAmerican |
5.877600E-02 |
| Caucasian-vs-Asian |
4.751000E-01 |
| AfricanAmerican-vs-Asian |
2.511200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.82962542286214E-12 |
| Normal-vs-Female |
1.63624669369256E-12 |
| Male-vs-Female |
6.443000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.96411808828634E-13 |
| Normal-vs-Age(41-60Yrs) |
3.45401485191132E-12 |
| Normal-vs-Age(61-80Yrs) |
2.26640928246979E-12 |
| Normal-vs-Age(81-100Yrs) |
1.759700E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.808200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.435800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.867800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.389800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.536200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.356200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.744070E-03 |
| Classical-VS-Follicular |
3.194400E-01 |
| Classical-VS-Other |
7.316400E-01 |
| Classical-VS-Normal |
1.60730317944058E-11 |
| Tall-VS-Follicular |
1.182800E-03 |
| Tall-VS-Other |
5.661000E-01 |
| Tall-VS-Normal |
1.65201186064223E-12 |
| Follicular-VS-Other |
5.572800E-01 |
| Follicular-VS-Normal |
1.65759994619208E-09 |
| Other-VS-Normal |
1.921670E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.11639594738244E-11 |
| Normal-vs-N1 |
1.68753899743024E-14 |
| N0-vs-N1 |
7.964200E-03 |
|
|
